Women's Health & Pregnancy Clinical Trials

Statistical methods in women's health & pregnancy trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All women's health & pregnancy trials

790 results

• MOVESIndependent statistical analysis of MOtiVating Endometrial Cancer Survivors With Activity Monitors and Tailored Feedback: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03820024).Phase NAResults postedn = 39NCT03820024
• Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide: Complete Statistical AnalysisIndependent statistical analysis of Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 4Results postedn = 9NCT02502864
• Multicenter, Prospective, Rand, PK Study of LCP-Tacro™ Compared to Prograf® Capsules in De Novo Adult Kidney Transplant: Complete Statistical AnalysisIndependent statistical analysis of Multicenter, Prospective, Rand, PK Study of LCP-Tacro™ Compared to Prograf® Capsules in De Novo Adult Kidney Transplant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2Results postedn = 36NCT01666951
• Multicultural Healthy Diet in Chronic Kidney Disease: Complete Statistical AnalysisIndependent statistical analysis of Multicultural Healthy Diet in Chronic Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05504850).Phase NAResults postedn = 18NCT05504850
• MyMenoPlan: Online Resource for Improving Women’s Menopause Knowledge and Informed Decision-making: Complete Statistical AnalysisIndependent statistical analysis of MyMenoPlan: Online Resource for Improving Women's Menopause Knowledge and Informed Decision-making: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 410NCT05299983
• MyPathIndependent statistical analysis of Patient-Centered Reproductive Decision Support Tool for Women Veterans: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04584294).Phase NAResults postedn = 465NCT04584294
• N30-005Independent statistical analysis of Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 1Results postedn = 24NCT01829919
• Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 59NCT00733408
• Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 40NCT01463072
• Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 3NCT02137252
• Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer: Complete Statistical AnalysisIndependent statistical analysis of Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 8NCT00328861
• Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I – II Trial: Complete Statistical AnalysisIndependent statistical analysis of Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 1/2Results postedn = 38NCT00041470
• NefigardIndependent statistical analysis of Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 365NCT03643965
• Neo ALTTOIndependent statistical analysis of Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00553358).Phase 3Results postedn = 455NCT00553358
• Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]: Complete Statistical AnalysisIndependent statistical analysis of Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03747120).Phase 2Results postedn = 138NCT03747120
• Neoadjuvant Immunotherapy in Brain Metastases: Complete Statistical AnalysisIndependent statistical analysis of Neoadjuvant Immunotherapy in Brain Metastases: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04434560).Phase 2Results postedn = 1NCT04434560
• Neoadjuvant Pazopanib in Renal Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Neoadjuvant Pazopanib in Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01361113).Phase 2Results postedn = 21NCT01361113
• Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 10NCT01167192
• Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2: Complete Statistical AnalysisIndependent statistical analysis of Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2: primary endpoint results, effect estimate…Phase 2Results postedn = 54NCT01593020
• NeohttpIndependent statistical analysis of Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02345772).Phase 1/2Results postedn = 4NCT02345772
• Neonatal Outcome by Reason for Delivery: Complete Statistical AnalysisIndependent statistical analysis of Neonatal Outcome by Reason for Delivery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01818518).Phase NAResults postedn = 995NCT01818518
• Neuraxial Preservative Free Morphine for Normal Spontaneous Vaginal Delivery: Complete Statistical AnalysisIndependent statistical analysis of Neuraxial Preservative Free Morphine for Normal Spontaneous Vaginal Delivery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04017442).Phase 4Results postedn = 160NCT04017442
• NFPIndependent statistical analysis of Nurse-Family Partnership Impact Evaluation in South Carolina: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03360539).Phase NAResults postedn = 5,670NCT03360539
• NIAGARAIndependent statistical analysis of Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 3Results postedn = 1,063NCT03732677
• Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC): Complete Statistical AnalysisIndependent statistical analysis of Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02389764).Phase 2Results postedn = 10NCT02389764
• Ninvasive Cardiac Output Measurements During Cesarean Delivery Under Spinal Anesthesia.: Complete Statistical AnalysisIndependent statistical analysis of Ninvasive Cardiac Output Measurements During Cesarean Delivery Under Spinal Anesthesia.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01928797).Phase NAResults postedn = 60NCT01928797
• Niraparib + Dostarlimab In BRCA Mutated Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Niraparib + Dostarlimab In BRCA Mutated Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04584255).Phase 2Results postedn = 66NCT04584255
• NIRVANAIndependent statistical analysis of A Study to Learn About How Elinzanetant Works and How Safe it is in Women Having Sleep Disturbances Associated With Menopause: primary endpoint results, effect estimate with confidence…Phase 2Results postedn = 110NCT06112756
• Nitrous Oxide for External Cephalic Version: Complete Statistical AnalysisIndependent statistical analysis of Nitrous Oxide for External Cephalic Version: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03502915).Phase 3Results postedn = 48NCT03502915
• NOLANIndependent statistical analysis of NOLAN: Naproxen or Loratadine and Neulasta: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01712009).Phase 2Results postedn = 600NCT01712009
• NOVA2Independent statistical analysis of Inhaled Nitric Oxide and Neuroprotection in Premature Infants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00515281).Phase 2/3Results postedn = 273NCT00515281
• NOVEMBERIndependent statistical analysis of Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 102NCT03345420
• NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours: Complete Statistical AnalysisIndependent statistical analysis of NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1/2Results postedn = 19NCT05714553
• Nutraceutical Efficacy for rUTI: Complete Statistical AnalysisIndependent statistical analysis of Nutraceutical Efficacy for rUTI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03395288).Phase 2/3Results postedn = 61NCT03395288
• OASISIndependent statistical analysis of Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04720664).Phase 2Results postedn = 11NCT04720664
• OASIS-1Independent statistical analysis of A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal…Phase 3Results postedn = 396NCT05042362
• OASIS-4Independent statistical analysis of A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy…Phase 3Results postedn = 474NCT05587296
• OlympiADIndependent statistical analysis of Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.: primary endpoint results,…Phase 3Results postedn = 302NCT02000622
• OMWaNAIndependent statistical analysis of Kangaroo Mother Care Before Stabilisation Amongst Low Birth Weight Neonates in Africa: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 2,221NCT02811432
• ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer: Complete Statistical AnalysisIndependent statistical analysis of ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 27NCT03485729
• ONTAKIndependent statistical analysis of A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 19NCT00880360
• Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only: Complete Statistical AnalysisIndependent statistical analysis of Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 35NCT00950911
• OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission: Complete Statistical AnalysisIndependent statistical analysis of OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission: primary endpoint results,…Phase 2Results postedn = 171NCT00857545
• Optimizing Decision Making About Breast Reconstruction After Mastectomy: A Patient-Centered Approach: Complete Statistical AnalysisIndependent statistical analysis of Optimizing Decision Making About Breast Reconstruction After Mastectomy: A Patient-Centered Approach: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 1Results postedn = 120NCT03346161
• Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation: Complete Statistical AnalysisIndependent statistical analysis of Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 76NCT01536392
• Oral Paricalcitol in Kidney Transplant Recipients: Complete Statistical AnalysisIndependent statistical analysis of Oral Paricalcitol in Kidney Transplant Recipients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00587158).Phase NAResults postedn = 100NCT00587158
• Oral Progesterone and Low Dose Aspirin in the Prevention of Preeclampsia: Complete Statistical AnalysisIndependent statistical analysis of Oral Progesterone and Low Dose Aspirin in the Prevention of Preeclampsia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 3NCT00719537
• ORANGEIndependent statistical analysis of Oral Amino Acid Nutrition to Improve Glucose Excursions in PCOS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03717935).Phase NAResults postedn = 27NCT03717935
• OrBITIndependent statistical analysis of Overactive Bladder Innovative Therapy Trial (OrBIT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00448175).Phase 4Results postedn = 100NCT00448175
• OReOIndependent statistical analysis of A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 220NCT03106987

← All therapeutic areas